In addition, SnapPath-processed samples can be subjected to next-generation sequencing. This boosts the potential for personalized medicine through the availability of highly valuable information about individual cancer patients and their reactions to targeted therapeutics. SnapPath can also be used to automate assays of cellular function using fluorescent molecular probes.
"Our research shows that this system is superior to most competitive platforms because it standardizes the processing of fresh tumor samples to enable improved downstream analysis of DNA, RNA and protein biomarkers," said
The SnapPath® diagnostics system enables the generation of PathMap™ functional signaling profiles, a new class of highly predictive algorithm-based tests that compare stimulated or inhibited patient samples to non-stimulated basal samples. PathMap profiles capture unique functional information about the dynamic behavior of tumor cells, particularly their signaling pathways, which cannot be obtained by static biomarker analysis based on gene mutations in dead, fixed samples.
The BioMarker Strategies SnapPath platform is compatible with multiple solid tumor sample types and the system ensures the health of the live tumor cells, allowing them to interact with stimulants and suppressors to generate functional information.
"This represents a milestone in cancer research, offering opportunities for the development of new drugs, predictive diagnostics, and research services," stated Van Cauwenberghe. "The utilization of these technologies may ultimately lead to a paradigm shift in investigational design as well as data management and processing."
The most promising application of SnapPath is in preclinical and early clinical drug studies to screen, measure and validate the efficacy of new drug candidates. Equally important is its significance in assessing pharmacodynamic responses to investigational drugs.
Moreover, SnapPath can be employed to develop a predictive test in late-stage clinical trials, enabling stratification of patients according to their clinical response. Such an approach will help clinicians better select the appropriate targeted therapy or combination of therapies for patients.
"Committed to accelerating the clinical translation of this technology to the industry, BioMarker Strategies is looking for pharmaceutical and biopharmaceutical partners that work with xenograft or tumorgraft models," added Van Cauwenberghe. "Such partnerships would not only strengthen the position of BioMarker Strategies as a leading innovating company in life sciences, but also constitute a key driver for clinical validation."
In recognition of these achievements,
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
Keywords for this news article include: Cancer, Therapy, Genetics, Oncology, Technology,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- BofA CEO Gets a 77 Percent Pay Bump
- Russia, Crimea Discuss Referendum
- Rand Paul Tells Rivals to Peddle Their Own Ideas
- Boeing Shares Fall on New Dreamliner Delay
- Goya Nutritionist Answers Demand for Healthy Hispanic Dishes
- Ukraine Crisis Sets U.S. Stocks Adrift
- Ukraine Says Russia Can't Have Crimea
- Gazprom Warns Ukraine to Pay Its Gas Bill
- FBI Investigating For-Profit Prison Company
- Alan Mulally Gets Big Payday From Ford